Printer Friendly

Nitric oxide determinations: much ado about N[O.sup.*]-thing?

The nitric oxide radical (N[O.sup.*]) is an important mediator of both physiological and pathophysiological processes. N[O.sup.*] is produced by nitric oxide synthase (NOS; EC 1.14.13.39), an enzyme that exists in three isoforms encoded by distinct genes [1, 2]. All isoforms of NOS catalyze the conversion of L-arginine into citrulline and N[O.sup.*]. In this reaction, which requires oxygen and NADPH, a guanidino-nitrogen atom of L-arginine is incorporated into N[O.sup.*]. Neuronal NOS (type I, nNOS) and endothelial (type III, eNOS) are [Ca.sup.2+]--and calmodulin-dependent constitutive NOS isoforms. nNOS has a function in neurotransmission. N[O.sup.*] produced by eNOS is identical to endothelium-derived relaxing factor and is the principal signal for relaxation of vascular smooth muscle cells. In addition, N[O.sup.*] produced by the endothelium has antithrombotic actions. Thus, eNOS and nNOS isoforms have important functions under normal conditions. They are present intracellularly, are rapidly activated by intracellular [Ca.sup.2+] fluxes, and produce small quantities of N[O.sup.*].

Inducible NOS (iNOS, type II) is not expressed under normal conditions.

iNOS is induced by cytokines and (or) endotoxin during inflammatory and infectious processes and produces abundant amounts of N[O.sup.*] for extended periods. iNOS can be induced in many cell types, including hepatocytes, macrophages, neutrophils, smooth muscle cells, and chondrocytes. Induction of iNOS requires de novo protein synthesis. N[O.sup.*] produced by iNOS has antimicrobial activity and may be involved in killing tumor cells. As such, it is part of the nonspecific host defense system. Increased expression of iNOS has been demonstrated in a wide range of disorders, including sepsis, asthma, rheumatoid arthritis, atherosclerotic lesions, tuberculosis, inflammatory bowel disease, Helicobacter pylori-induced gastritis, allograft rejection, Alzheimer disease, and multiple sclerosis [3-14]. It has been postulated that excessive and continuous production of N[O.sup.*] is responsible for at least part of the symptoms in these disorders.

Considering the normal functions of N[O.sup.*] and the wide range of pathological conditions in which it has been implicated, interest in measuring N[O.sup.*] production has, not surprisingly, received enormous attention recently [15]. Many different methods for determining N[O.sup.*] or its metabolites nitrite and nitrate have been reported. The most relevant for the clinical chemist are briefly discussed here.

METHODS FOR DETERMINING N[O.sup.*] AND METABOLITES

"Real-time" N[O.sup.*] determination. Several methods for "real-time" N[O.sup.*] production have been reported. These methods detect ongoing N[O.sup.*] production in viable biological samples such as tissue explants, biopsies, or isolated cells (e.g., leukocytes or peritoneal exudate cells). Electrochemical methods use N[O.sup.*]-sensitive microsensors, e.g., Clark-type and porphyrinic electrodes [15-17]. Recently, a microsensor based on a porphyrinic electrode was applied in vivo to humans [17]. N[O.sup.*] can also be detected by chemiluminescence [15,18] in an assay based on the reaction of N[O.sup.*] with ozone to yield *N[O.sub.2] and light. N[O.sup.*] produced by viable biological samples reacts with ozone in the gas phase in a sealed compartment (headspace gas method). The emitted light can be detected with a photomultiplier tube. The same principle is used to measure N[O.sup.*] in exhaled air. Finally, N[O.sup.*] can be determined by a spectrophotometric assay in which N[O.sup.*] reacts with ferrous oxyhemoglobin (Hb[O.sub.2]) to yield nitrate and methemoglobin [15,18,19]. The formation of methemoglobin can be monitored by measuring the increase in absorbance at 401 nm. This method is suitable for in vitro and ex vivo measurements of N[O.sup.*] in viable biological samples. The advantage of these methods is that actual N[O.sup.*] formation is determined. Their disadvantages are technical complexity and the requirement for viable biological samples. Accordingly, these methods are not suitable for body fluids devoid of cells. In addition, application of this method in vivo is difficult and has been described for only the electrochemical sensors [17].

Determination of stable end-products nitrite/nitrate. The N[O.sup.*] radical is rapidly metabolized into the stable end-products nitrite and nitrate. In most body fluids, including plasma, most of the nitrite is converted to nitrate; thus determination of nitrite alone is meaningless [20]. The most commonly used nitrite assay is based on the Griess diazotization reaction, which is specific for nitrite and does not detect nitrate. Therefore, nitrate in samples must first be reduced to nitrite; subsequent nitrite determination thus yields the total nitrite + nitrate concentration of the sample. Reduction of nitrate to nitrite can be performed by treating the samples with nitrate reductase [20,21], copperized cadmium [22] or hydrazine [23]. Nitrite and nitrate can also be determined in body fluids by HPLC [24], capillary electrophoresis [25,26], or anion-exchange chromatography [27]. Nitrite and nitrate ions are then detected by UV absorbance or conductivity.

In this issue of Clinical Chemistry, Yang et al. [28] describe a very sensitive method for chemiluminescent detection of nitrite and nitrate. Nitrite and nitrate are first reduced to N[O.sup.*], which is then reacted with ozone and detected by chemiluminescence in the gas phase as already described. The authors evaluated their method with respect to reproducibility, recovery, and reduction conditions. The importance of this method is the application of chemiluminescence to the detection of nitrite and nitrate, making this method more sensitive than most others currently used to measure nitrite and nitrate.

Methods for determining nitrite and nitrate are applicable to both fresh and archived body fluids such as plasma, serum, urine, bile, synovial fluid, sputum, and cerebrospinal fluid. Advantages are the potential for automation and high throughput. A drawback is that such methods also detect nitrate derived from non-N[O.sup.*] sources such as diet. The exact contribution of diet or other non-N[O.sup.*] sources is uncertain. Fasting for 12 h is reported to reduce concentrations of plasma nitrate and nitrite by 50%, and in fasted healthy volunteers ~90% of plasma nitrite and nitrate is derived from NOS-derived N[O.sup.*] [29,30]. Another disadvantage is that determination of nitrite and nitrate does not demonstrate ongoing N[O.sup.*] production. Considering that the half-life of nitrate in plasma is ~1.5 h [31], increased concentrations of nitrate in plasma at least indicate recent N[O.sup.*] production.

Incorporation of stable heavy nitrogen isotopes into nitrite and nitrate. In this technique, [[sup.15]N]-guanidino-labeled L-arginine is administered to subjects [29, 30]. As catalyzed by NOS, the [sup.15]N at the guanidino position of L-arginine ends up in nitrite and nitrate. Enrichment of nitrite and nitrate with [sup.15]N can be determined by GC-MS and is taken as a measure of NOS activity [29,31]. The advantages of this method are its specificity for nitrite and nitrate derived from NOS activity and its potential to measure actual N[O.sup.*] production in vivo in humans. Disadvantages are technical complexity and costs.

Determination of NOS activity. NOS enzyme activity is assayed by measuring the conversion of radiolabeled L-arginine into radiolabeled citrulline. This method is very sensitive and specific but requires tissue or cells. The assay can be performed on fresh material such as leukocytes and peritoneal exudate cells [32] or gastric and intestinal biopsies [9, 33, 34]. The assay can also be performed on homogenates of frozen tissue or cells, provided the material is nonfixed, snap-frozen in liquid nitrogen, and stored at -80 [degrees]C. Increased NOS activity, preferably in comparison with that in control preparations, indicates induction of iNOS and inflammation. Disadvantages of this method are the requirement for tissue or cells and the necessity for handling radioactive materials.

Spectroscopy: electron paramagnetic resonance (EPR) and near-infrared. The unpaired electron of N[O.sup.*] can be detected by EPR spectroscopy after reaction with a spin-trap compound, i.e., a compound that reacts with radicals to form relatively stable paramagnetic species that can be detected by EPR spectroscopy [15,18]. Heme-containing proteins, particularly hemoglobin, can act as an N[O.sup.*] spin trap; the resulting nitrosylferroheme complexes can be detected by EPR spectroscopy [15,18]. EPR spectroscopy can be applied to erythrocytes, whole blood, or tissue specimens [15,35]. Because nitrosylferroheme complexes are relatively stable, stored material can be used for EPR spectroscopy. Recently, EPR spectroscopy with novel spin traps has been applied to detect ongoing N[O.sup.*] production in vivo [36, 37]. EPR spectroscopy requires specialized equipment and expertise. In addition, reactions of N[O.sup.*] and nitrite with methemoglobin and oxyhemoglobin can interfere with the nitrosylferrohemoglobin EPR signal. Finally, near-infrared spectroscopy has been described as a technique to detect nitrosylhemoglobin formation in vivo [38].

MEANING AND VALUE OF NITRITE AND NITRATE DETERMINATIONS

The choice for a particular technique will depend on the material available for analysis, the requested information, and the requirements for sensitivity, specificity, and speed of analysis. For routine application in a clinical chemistry laboratory, the nitrite + nitrate combination is usually measured: This determination can be applied to various body fluids, is amenable to automation, and has a high throughput. Therefore, it is important to establish the meaning and value of nitrite and nitrate determinations in body fluids. Increased nitrite + nitrate concentrations in body fluids other than blood or urine could be indicators of local inflammatory processes, as has been suggested for synovial fluid (rheumatoid arthritis) [39], bronchoalveolar lavage fluid (lung cancer) [40], sputum or saliva (inflammatory lung disorders), peritoneal fluid or ascites (peritonitis) [41], and cerebrospinal fluid (severe head injury and meningitis) [42-45]. Whether the increased nitrite + nitrate concentrations in cerebrospinal fluid during meningitis are related to increased production of N[O.sup.*] in the brain or to increased permeability of the blood-brain barrier remains to be elucidated [44, 45]. Above-normal concentrations of nitrite and nitrate in these compartments presumably reflect recent or ongoing increased N[O.sup.*] production. However, still to be established is whether the nitrite and nitrate in a particular compartment are exclusively derived from the tissue(s) or organ(s) draining into that compartment.

The most common body fluids in which nitrite and nitrate determinations are performed are plasma (serum) and urine. Among the aspects to be considered when measuring nitrite and nitrate in serum or plasma are:

1) The half-time of nitrite and nitrate persistence in blood [30]. Under ordinary conditions, nitrite and nitrate are rapidly excreted into urine. This implies that increased serum concentrations of nitrite and nitrate indicate only ongoing or recently increased N[O.sup.*] production.

2) The effect of kidney function. Increased nitrite and nitrate concentrations do not always indicate increased production when kidney function is compromised, as was recently shown for patients with liver cirrhosis and ascites [46]. Conversely, normal nitrite and nitrate concentrations do not always rule out increased production when kidney function is normal. In this regard, determining both total daily nitrite and nitrate excretion into urine as well as plasma nitrite and nitrate concentrations could be an accurate indication of total nitrite and nitrate production.

3) Sensitivity. Determination of plasma nitrite and nitrate may not be sensitive enough to detect moderate or local N[O.sup.*] production and inflammation, because of dilution in the large blood volume.

Determination of urinary nitrite + nitrate output as a marker of inflammation has been reported for inflammatory bowel disease, allograft rejection, arthritis, gastroenteritis, and bacterial translocation [33,47-50]. However, the inter- and intraindividual urinary nitrate measurements are highly variable and dependent on diet [20, 31, 51]. When collecting urine for nitrite + nitrate determinations, one must take precautions to prevent bacterial growth in urine, especially in patients with urinary tract infections, because bacteria are potent producers of nitrate. Collection of urine on ice and (or) adding antibiotics or isopropanol to the urine during collection is recommended.

Potentially useful applications of the determination of nitrite + nitrate in plasma or urine are (a) diagnosis and monitoring of local or systemic inflammatory processes, (b) diagnosis and monitoring of allograft rejection [52], (c) monitoring of anti-inflammatory or immunosuppressive therapy, (d) adjustment of dosage of therapeutically used NOS inhibitors, and (e) adjustment of dosage of therapeutically applied inhaled N[O.sup.*], to avoid side-effects [53]. Future studies need to tell us whether nitrite + nitrate determinations are really valuable in these applications.

BEYOND N[O.sup.*]

Clearly, the real value of determinations of N[O.sup.*] or its metabolites nitrite and nitrate in clinical practice still need to be proved. One of the major disadvantages of measuring nitrite and in particular nitrate is that these ions are naturally occurring. In addition, the range of normal values in body fluids is variable and diet-dependent. This limits the sensitivity and specificity of this assay as a marker of N[O.sup.*] production and inflammation and raises the question as to whether more-sensitive and specific markers of inflammation or tissue damage exist. In this respect, 3-nitrotyrosine may be a promising candidate. 3-Nitrotyrosine is formed when peroxynitrite, the result of the reaction of N[O.sup.*] with superoxide anions, acts on tyrosine residues in proteins [54]. Simultaneous production of N[O.sup.*] and superoxide anions is likely during inflammation [54]. Indeed, 3-nitrotyrosine residues in proteins have been demonstrated in many inflammatory disorders [6,8,10,11,55-59]. Turnover of proteins containing 3-nitrotyrosine residues yields free 3-nitrotyrosine. Free 3-nitrotyrosine has been detected in plasma and synovial fluid of patients with rheumatoid arthritis [59]. Methods to measure free 3-nitrotyrosine in body fluids and protein-bound 3-nitrotyrosine in tissue specimens after total protein hydrolysis are currently being developed [58-60]. Interest in the determination of 3-nitrotyrosine as a marker of inflammation and exposure to peroxynitrite is expected to increase.

In conclusion, the methodology is now operational to determine NOS, N[O.sup.*], and metabolites such as nitrite, nitrate, and 3-nitrotyrosine in body fluids and tissue specimens. What needs to be established next is the value of these determinations in clinical practice.

References

[1.] Knowles RG, Moncada S. Nitric oxide syntheses in mammals [Review]. Biochem J 1994;298:249-58.

[2.] Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.

[3.] Buttery LDK, Evans TJ, Springall DR, Carpenter A, Cohen J, Polak JM. Immunochemical localization of inducible nitric oxide synthase in endotoxin-treated rats. Lab Invest 1994;71:755-64.

[4.] Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, et al. Induction of nitric oxide synthase in asthma. Lancet 1993;342: 1510-3.

[5.] Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995;96:2357-63.

[6.] Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996;75:77-85.

[7.] Nicholson S, da Gloria Bonecini-Almeida M, Lapa e Silva JR, Nathan C, Xie Q, Mumford R, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996;183:2293302.

[8.] Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996;111: 871-85.

[9.] Godkin AJ, De Belder AJ, Villa L, Wong A, Beesley JE, Kane SP, Martin JF. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996;26:867-72.

[10.] Miller MUS, Thompson JH, Zhang X-J, Sadowska-Krowicka H, Kakkis JL, Munshi UK, et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995;109: 1475-83.

[11.] Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang X-J, Ruiz B, et al. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in Helicobacter pylori gastritis: effects of antibiotics and antioxidants. Cancer Res 1996; 56:3238-43.

[12.] Kuo PC, Alfrey EJ, Krieger NR, Abe KY, Huie P, Sibley RK, Dafoe DC. Differential localization of allograft nitric oxide synthesis: comparison of liver and heart transplantation in the rat model. Immunology 1996;87:647-53.

[13.] Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie Q-W, Smith TW, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184:1425-33.

[14.] Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995;92: 12041-5.

[15.] Nitric oxide. Part A. Sources and detection of NO; NO synthase. Methods Enzymol 1996;268:3-515.

[16.] Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature 1992;358:676-8.

[17.] Valiance P, Patton S, Bhagat K, MacAllister R, Radomski M, Moncada S, Malinski T. Direct measurement of nitric oxide in human beings. Lancet 1995;346:153-4.

[18.] Archer S. Measurement of nitric oxide in biological models. FASEB J 1993;7:349-60.

[19.] Murphy ME, Noack E. Nitric oxide assay using hemoglobin method. Methods Enzymol 1994;233:240-50.

[20.] Moshage H, Kok B, Huizenga JR, Jansen PLM. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995;41:892-6.

[21.] Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem 1995;41: 904-7.

[22.] Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-8.

[23.] Kemperers AJ, Luft AG. Re-examination of the determination of environmental nitrate as nitrite by reduction with hydrazine. Analyst 1988;113:111720.

[24.] Muscara MN, de Nucci G. Simultaneous determination of nitrite and nitrate anions in plasma, urine and cell culture supernatants by high-performance liquid chromatography with post-column reactions. J Chromatogr B 1996; 686:157-64.

[25.] Ueda T, Maekawa T, Sadamitsu D, Oshita S, Ogino K, Nakamura K. The determination of nitrite and nitrate in human blood plasma by capillary zone electrophoresis. Electrophoresis 1995;16:1002-4.

[26.] Leone AM, Francis PL, Rhodes P, Moncada S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem Biophys Res Commun 1994;200:951-7.

[27.] Everett SA, Dennis MF, Tozer GM, Prise VE, Wardman P, Stratford MRL. Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography. J Chromatogr A 1995;706:437-42.

[28.] Yang F, Troncy E, Francoeur M, Vinet B, Vinay P, Czaika G, Blaise G. Effect of reducing reagents and temperatures on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence. Clin Chem 1997;43:657-62.

[29.] Rhodes PM, Leone AM, Francis PL, Struthers AD, Moncada S. The L-arginine: nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995;209:590-6.

[30.] Castillo L, Beaumier L, Ajami AM, Young VR. Whole body nitric oxide synthesis in healthy men determined from [[sup.15]N]arginine-to-[[sup.15]N]citrulline labeling. Proc Natl Acad Sci U S A 1996;93:11460-5.

[31.] Veszelovsky E, Holford NHG, Thomsen LL, Knowles RG, Baguley BC. Plasma nitrate clearance in mice: modelling of the systemic production of nitrate following the induction of nitric oxide synthesis. Cancer Chemother Pharmacol 1995;36:155-9.

[32.] Steil AA, Garcia-Rodriguez MC, Alonso A, Crespo MS, Bosca L. Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br J Pharmacol 1995;114:895-901.

[33.] Ribbons KA, Zhang X-J, Thompson JH, Greenberg SS, Moore WM, Kornmeier CM, et al. Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. Gastroenterology 1995;108:705-11.

[34.] Rachmilewitz D, Karmeli F, Eliakim R, Stalnikowicz R, Ackerman Z, Amir G, Stamler JS. Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients. Gut 1994;35:1394-7.

[35.] Chamulitrat W, Jordan SJ, Mason RP. Nitric oxide production during endotoxic shock in carbon tetrachloride-treated rats. Mol Pharmacol 1994;46: 391-7.

[36.] Reinke LA, Moore DR, Kotake Y. Hepatic nitric oxide formation: spin trapping detection in biliary efflux. Anal Biochem 1996;243:8-14.

[37.] Wallis G, Brackett D, Lerner M, Kotake Y, Bolli R, McCay PB. In vivo spin trapping of nitric oxide generated in the small intestine, liver, and kidney during the development of endotoxemia: a time-course study. Shock 1996; 6:274-8.

[38.] Ohdan H, Fukuda Y, Suzuki S, Amemiya H, Dohi K. Simultaneous evaluation of nitric oxide synthesis and tissue oxygenation in rat liver allograft rejection using near-infrared spectroscopy. Transplantation 1995;60:530-5.

[39.] Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996;23:230-6.

[40.] Arias-Diaz J, Vara E, Torres-Melero J, Garcia C, Baki W, Ramirez-Armengol JA, Balibrea JL. Nitrite/nitrate, cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 1994;74:1546-51.

[41.] Kim YM, Hong SJ, Billiar TR, Simmons RL. Counterprotective effect of erythrocytes in experimental bacterial peritonitis is due to scavenging of nitric oxide and reactive oxygen intermediates. Infect Immun 1996;64: 3074-80.

[42.] Clark RS, Kochanek PM, Obrist WD, Wong HR, Billiar TR, Wisniewski SR, Marion DW. Cerebrospinal fluid and plasma nitrite and nitrate concentrations after head injury in humans. Crit Care Med 1996;24:1243-51.

[43.] Wong ML, Rettori V, AI-Shekhlee A, Bongiorno PB, Canteros G, McCann SM, et al. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nature Med 1996;2:581-4.

[44.] Kornelisse RF, Hoekman K, Visser JJ, Hop WC, Huijmans JG, Van der Straaten PJ, et al. The role of nitric oxide in bacterial meningitis in children. J Infect Dis 1996;174:120-6.

[45.] Buster BL, Weintrob AC, Townsend GC, Scheld WM. Potential role of nitric oxide in the pathophysiology of experimental bacterial meningitis in rats. Infect Immun 1995;63:3835-9.

[46.] Campillo B, Bories PN, Benvenutti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol 1996;24:707-14.

[47.] Winlaw DS, Schyvens CG, Smythe GA, Du Z, Rainer SP, Keogh AM, et al. Urinary nitrate excretion is a noninvasive indicator of acute cardiac allograft rejection and nitric oxide production in the rat. Transplantation 1994;58: 1031-6.

[48.] Stichtenoth DO, Gutzki FM, Tsikas D, Selve N, Bode-Boger SM, Boger RH, Frolich JC. Increased urinary nitrate excretion in rats with adjuvant arthritis. Ann Rheum Dis 1994;53:547-9.

[49.] Dykhuizen RS, Copland M, Smith CC, Douglas G, Benjamin N. Plasma nitrate concentration and urinary nitrate excretion in patients with gastroenteritis. J Infect 1995;31:73-5.

[50.] Oudenhoven IMJ, Klaasen HLBM, Lapre JA, Weerkamp AH, van der Meer R. Nitric-oxide derived urinary nitrate as a marker of intestinal bacterial translocation in rats. Gastroenterology 1994;107:47-53.

[51.] Egberts J, Soederhuizen W. Urine samples before dinner are preferable when studying changes in endogenous nitrate production under uncontrolled dietary conditions. Clin Chim Acta 1996;254:141-8.

[52.] Devlin J, Palmer RMJ, Gonde CE, O'Grady J, Heaton N, Tan KC, et al. Nitric oxide generation: a predictive parameter of acute allograft rejection. Transplantation 1994;58:592-5.

[53.] Hovenga S, Koenders MEF, van der Werf TS, Moshage H, Zijlstra JG. Methaemoglobinaemia after inhalation of nitric oxide for treatment of hydrochlorothiazide-induced pulmonary oedema. Lancet 1996;348: 1034-5.

[54.] Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly [Review]. Am J Physiol 1996;271:C1424-37.

[55.] MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996;93:11853-8.

[56.] Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-8.

[57.] Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994;94:2407-13.

[58.] Ischiropoulos H, AI-Mehdi AB, Fisher AB. Reactive species in ischemic rat lung injury: contribution of peroxynitrite. Am J Physiol 1995;269:L158-64.

[59.] Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. FEBS Lett 1994;350:9-12.

[60.] Kamisaki Y, Wada K, Nakamoto K, Kishimoto Y, Kitano M, Itch T. Sensitive determination of nitrotyrosine in human plasma by isocratic high-performance liquid chromatography. J Chromatogr B 1996;685:343-7.

Han Moshage

Groningen Institute for Drug Studies

Department of Medicine

Division of Gastroenterology and Hepatology

University Hospital Groningen

PO Box 30.001

NL-9700 RB Groningen

The Netherlands

Fax +31-50-3614756

E-mail h.moshage@med.rug.nl
COPYRIGHT 1997 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Editorial
Author:Moshage, Han
Publication:Clinical Chemistry
Date:Apr 1, 1997
Words:4111
Previous Article:Meetings.
Next Article:Rapid screening method for detecting mutations in the 21 -hydroxylase gene.
Topics:


Related Articles
Gas therapy for sickle-cell anemia.
Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus /...
Possible nitric oxide modulation in protective effect of (Curcuma longa, Zingiberaceae) against sleep deprivation-induced behavioral alterations and...
Effect of nitric oxide on oxygenation in lung injury after surgery for ruptured abdominal aneurysm.
Nitric oxide signalling in plants.
Genotype-specific influence on nitric oxide synthase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells.
Increases in nitric oxide concentrations correlate strongly with body fat in obese humans.
Semiautomated measurement of nitrate in biological fluids.
Effects of reducing reagents and temperature on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters